The Brigham and Women's Hospital, Inc.

The General Hospital Corporation

Beth Israel Deaconess Medical Center, Inc.

Velico Medical, Inc.

Harvard College

Children's Medical Center Corporation

Biogen, Incorporated

Bloodcenter Research Foundation

Zymequest, Inc.

University of Pennsylvania

Thomas P Stossel

Paul A Janmey

John H Hartwig

Stuart E Lind

Po-Shun Lee

Henrik Clausen

Karin M Hoffmeister

Andrej Tarkowski

Ravi Thadhani

Ananth Karumanchi

Roland Vegner

C Casey Cunningham

Teresia Anna Charlotta Magnuson Osborn

George M Whitesides

Carlo Brugnara

Keith Rosiello

Charles R Mace

Hans H Wandall

Ashok A Kumar

Matthew Reiser Patton

Katarzyna Maresz

Robert Bucki

Caeul Lim

Anna Charlotta Teresia Magnuson Osborn

Jonathan W Hennek

Bonnie Dittel

Jennifer A Lamb

Yovany Moreno

Manoj T Duraisingh

Si-yi Ryan Lee

Gaetana D'Alesio-Spina

Eric Leuchovius, Legal Representative

Richard Chaby

Anna Charlotta Teresia Magnusson Osborn

Hans Wandall

Clausen Henrik

The invention is directed, in part, to the use of gelsolin to diagnose, monitor, and treat subjects with renal failure (e.g., chronic renal failure subjects on dialysis).

Diagnostic and therapeutic uses of gelsolin in renal failure

The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis).

Methods for treating or reducing the risk of arthritis in a subject by administering gelsolin

The invention relates to the use of gelsolin to treat infections and to monitor the treatment of infections. The invention also provides methods up-regulating interleukin expression and methods for down-regulating pro-inflammatory cytokine expression.

Use of gelsolin to treat infections

An aqueous multi-phase system for diagnosis of sickle cell disease is described, including two or more phase-separated phases including: a first aqueous phase including a first phase component and having a first density between about 1.025 g/cmand about 1.095 g/cm; and a second aqueous phase including a second phase component and having a second density between about 1.100 g/cmand about 1.140 g/cm; wherein the first density is lower than the second density; and each of the first and second phase components include at least one polymer.

Multiphase systems for diagnosis of sickle cell disease

Use of gelsolin to diagnose and treat inflammatory diseases

The invention relates to the use of gelsolin to treat neurologic diseases (e.g., multiple sclerosis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of neurologic diseases.

Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel)

The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis.

Prolonging survival of platelets using CMP-sialic acid,UDP-galactose or both

Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis

Methods for prolonging survival of platelets using UDP-galactose

Compositions and methods for prolonging survival of platelets

Methods and compositions for preserving platelets at cryogenic temperatures with retention of hemostatic activity are provided. The compositions include a first agent for inhibiting actin filament severing and a second agent for inhibiting actin polymerization. Contacting the platelets with the first and second agents prior to exposure to cold temperature prevents cold-induced platelet activation.

Preservation of blood platelets

Methods and compositions for facilitating the transport of a membrane-impermeable extracellular agent having an intracellular activity across the membrane of a cell are provided. The methods involve covalently coupling an amino terminal blocking group to a transport-mediating peptide to form a carrier molecule. The carrier molecule is covalently coupled to the extracellular agent to form a membrane-permeable prodrug. The transport-mediating peptides are highly basic and bind to polyphosphoinositides.

Polyphoshoinositide binding peptides for intracellular drug delivery

Polyphosphoinsitide binding peptides for intracellular drug delivery

The present invention relates to therapeutic methods wherein an actin-binding protein, preferably gelsolin or DBP, is administered to a patient with actin-containing clots in order to remove actin from the clots. The invention also relates to diagnostic methods in which actin is removed from an actin-containing clot in vitro and quantitated.

Effects of actin filaments of fibrin clot structure and lysis

Growing community of inventors

Belmont, MA, United States of America

Thomas P Stossel